Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 9/20 | 0.60 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.50 |
| ▸ | HTR1D known ✓ | P28221 | 2/20 | 0.45 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.43 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.42 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.42 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.42 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | MPO | P05164 | 3/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7816067 | 0.98 | HTR2A (0.62) | NPSR1MAPTSMN1; SMN2HTR2AMPO | |
| Hydrochloric Acid SCHEMBL7816288 | 0.84 | NPSR1 (0.67) | NPSR1MAPTSMN1; SMN2HTR2AMPO | |
| SCHEMBL7822472 | 0.82 | HTR2A (0.66) | NPSR1MAPTSMN1; SMN2HTR2AMPO | |
| Hydrochloric Acid SCHEMBL7808193 | 0.81 | NPSR1 (0.63) | NPSR1MAPTSMN1; SMN2HTR2AMPO | |
| SCHEMBL7808257 | 0.79 | HTR2A (0.58) | NPSR1MAPTSMN1; SMN2HTR2AMPO | |
| SCHEMBL7818210 | 0.79 | HTR2A (0.62) | NPSR1MAPTSMN1; SMN2HTR2AMPO | |
| SCHEMBL8200957 | 0.78 | MPO (0.50) | NPSR1MAPTSMN1; SMN2HTR2AMPO | |
| SCHEMBL21802235 | 0.78 | SMN1; SMN2 (0.46) | NPSR1MAPTSMN1; SMN2HTR2AMPO | |
| SCHEMBL8200955 | 0.78 | HTR2A (0.49) | NPSR1MAPTSMN1; SMN2HTR2AMPO | |
| Hydrochloric Acid SCHEMBL31109030 | 0.78 | MAPT (1.00) | NPSR1MAPTSMN1; SMN2HTR2AMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0749313-A4 | METHOD FOR TREATING 5HT 2B RECEPTOR RELATED CONDITIONS | LILLY CO ELI (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6090945-A | HIGH AFFINITY FOR THE 5-HT1C RECEPTOR. | ELI LILLY AND COMPANY (US) | 2000-07-18 | — | — | US | disclosed |
| US-5861425-A | CENTRAL NERVOUS SYSTEM DISORDERS FOR TREATMENT OF ANXIETY, | ELI LILLY AND COMPANY (US) | 1999-01-19 | — | — | US | disclosed |
| US-5760051-A | CENTRAL NERVOUS SYSTEM | ELI LILLY AND COMPANY (US) | 1998-06-02 | — | — | US | disclosed |
| US-5736544-A | ADMINISTERING TO TREAT MIGRAINE HEADACHES IN MAMMALS | ELI LILLY AND COMPANY (US) | 1998-04-07 | — | — | US | disclosed |
| US-5705519-A | ADMINISTERING A SUBSTITUTED INDOLE TO A MAMMAL | ELI LILLY AND COMPANY (US) | 1998-01-06 | — | — | US | disclosed |
| US-5688807-A | ANTIDEPRESSANTS, ANXIETY, UROGENITAL DISORDERS, HYPOTENSIVES, CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0751770-A4 | 8-SUBSTITUTED TETRAHYDRO-BETA-CARBOLINES | LILLY CO ELI (US) | 1997-06-11 | — | — | EP | disclosed |
| US-5635528-A | RECEPTOR BINDING MODULATORS, FOR CENTRAL NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1997-06-03 | — | — | US | disclosed |
| US-5631265-A | CHEMICAL INTERMEDIATES WITH CENTRAL NERVOUS SYSTEM ACTIVITY | ELI LILLY AND COMPANY (US) | 1997-05-20 | — | — | US | disclosed |
| US-5508284-A | TREATING 5-HYDROXYTRYPTAMINE MODULATION | ELI LILLY AND COMPANY (US) | 1996-04-16 | — | — | US | disclosed |
| US-5500431-A | ANTISEROTONINE AGENTS; SEXUAL AND EATING DISORDERS | ELI LILLY AND COMPANY (US) | 1996-03-19 | — | — | US | disclosed |
| US-5488053-A | Tetrahydro-pyrido-indole | ELI LILLY AND COMPANY (US) | 1996-01-30 | — | — | US | disclosed |
| WO-1995024200-A1 | METHOD FOR TREATING 5HT2B RECEPTOR RELATED CONDITIONS | ELI LILLY AND COMPANY (US) | 1995-09-14 | — | — | WO | disclosed |
| WO-1995024191-A1 | 8-SUBSTITUTED TETRAHYDRO-BETA-CARBOLINES | ELI LILLY AND COMPANY (US) | 1995-09-14 | — | — | WO | disclosed |
| WO-1994024132-A1 | TETRAHYDRO-PYRIDO-INDOLE | ELI LILLY AND COMPANY (US) | 1994-10-27 | — | — | WO | disclosed |
| WO-1994023720-A1 | TETRAHYDRO-BETA-CARBOLINES | ELI LILLY AND COMPANY (US) | 1994-10-27 | — | — | WO | disclosed |
| EP-0620223-A2 | Tetrahydro-pyrido-indole | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |
| EP-0620222-A2 | Tetrahydro-beta-carbolines | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |
| US-5300645-A | Condensation of cycloalkyl-, phenyl- or naphthylpyrrole ethylamines with a 2-oxazolidinone to get antiserotonine agent | ELI LILLY AND COMPANY (US) | 1994-04-05 | — | — | US | disclosed |